Business Wire

MATRIXX Software Achieves 5G Performance Benchmarks with IBM Cloud for Telecommunications

3.5.2021 13:02:00 EEST | Business Wire | Press release

Share

MATRIXX Software, a global leader in cloud native, 5G monetization solutions, today announced performance results from its IBM Cloud for Telecommunications implementation. Anticipating the urgent need of Communications Service Providers (CSPs) to monetize their 5G investments, MATRIXX Software’s 5G CCS established a performance milestone of 200K transactions per second (TPS) across 100M subscribers running on IBM Cloud for Telecommunications.

With average end-to-end latency of 7.4 milliseconds across all operations, including network gateways and routing, this performance benchmark demonstrates that MATRIXX on IBM Cloud can enable CSPs to run critical network workloads in the cloud at the same or better performance levels as on-premise. MATRIXX successfully delivered seamless scalability for an efficient, flexible cloud native charging solution, which opens the door for CSPs to experiment with new ways of monetizing 5G workloads.

This is an important milestone as 5G represents a $667B opportunity by 2026 and impacts every industry. To explore and test new revenue streams, CSPs need to accelerate their network transformation to handle increased traffic from new services and devices. With more than 30 billion IoT devices predicted by 2025, telco networks and IT infrastructure will need proven capability to scale both vertically and horizontally if they are to manage the 10-20x growth in traffic anticipated from 5G.

Using a simulated blend of 4G and 5G traffic, MATRIXX used the IBM Cloud for Telecommunications, built on Red Hat OpenShift, to provide more flexibility in harnessing data across cloud and on-premises environments. The performance benchmark demonstrates how together, MATRIXX and IBM Cloud for Telecommunications can deliver consistent throughput and latency, which helps enable providers to run critical network workloads such as charging in the cloud.

“As telcos deploy 5G network infrastructure, they are looking for validation of new revenue models that 5G enables,” said Marc Price, MATRIXX CTO. “We have collaborated with IBM to achieve industry-leading metrics on its IBM Cloud for Telecommunications, showcasing for CSPs how their 5G monetization strategies will be achievable as the number and diversity of connected devices increases exponentially.”

This is the first lab outcome since MATRIXX joined IBM’s partner ecosystem. These results demonstrate the seamless scalability of MATRIXX’s patented converged charging technology when combined with the IBM Cloud for Telecommunications. Working in close collaboration, IBM’s Hybrid Cloud Build Team and MATRIXX have developed a blueprint for best practices and configuration requirements they can deliver to CSP’s to address their unique performance targets.

“As 5G transforms the telco industry, many operators face the challenge of managing growing volumes of data, voice, and multi-media services from millions of end users. The IBM Cloud for Telecommunications is designed to address these specific challenges and transform their networks into flexible platforms that can efficiently scale,” said Steve Goetz, Vice President & Senior Partner of Global Telecommunications, Media & Entertainment Industry at IBM. “As a leading Network and 5G Transformation partner, IBM Global Business Services is proud to support our ecosystem partner MATRIXX to help them achieve such a notable milestone. These results will accelerate business transformation and agility as customers modernize enterprise applications and infrastructure to unlock the power of 5G and edge.”

With innovations in business rule execution, transaction processing, data management and clustering, the cloud native MATRIXX 5G CCS delivers consistent throughput and latency within heterogenous network environments, managing sophisticated price plans, across hundreds of millions of unique subscribers and devices.

MATRIXX is part of IBM's partner ecosystem collaborating on the IBM Cloud for Telecommunications to help network equipment providers, independent software vendors (ISVs), software-as-a-service providers, and hardware partners accelerate business transformation by unlocking the power of 5G and edge. The IBM Cloud for Telecommunications is an open, hybrid cloud architecture that leverages Red Hat OpenShift and IBM Cloud Satellite to enable clients to deploy IBM Cloud services anywhere: on the cloud, on premises or at the edge, while addressing unique industry regulatory and security requirements. The IBM Hybrid Cloud Build Team is an elite team dedicated to help partners maximize the value of open hybrid cloud environments and unlock the power of AI for their business and customers.

To learn more about the collaboration between MATRIXX and IBM, watch this video interview between Marc Price and Omkar Nimbalkar, VP WW Hybrid Cloud Build Team at IBM Hybrid Cloud Ecosystem Group.

About MATRIXX Software

MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS), enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jennifer Kyriakakis
mediainquiry@matrixx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye